NOTCH4 mutation as predictive biomarker for immunotherapy benefits in NRAS wildtype melanoma

BACKGROUND: NRAS wildtype melanoma accounts for approximately 80% of melanomas. Previous studies have shown that NRAS wildtype melanoma had higher response rates and better prognoses than NRAS-mutant patients following immunotherapy, while as major actors in tumor cells and tumor microenvironment (T...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hongxia, Zhang, Qin, Duan, Qianqian, Tan, Yuan, Sun, Tingting, Qi, Chuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372281/
https://www.ncbi.nlm.nih.gov/pubmed/35967450
http://dx.doi.org/10.3389/fimmu.2022.894110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9372281/
https://www.ncbi.nlm.nih.gov/pubmed/35967450
http://dx.doi.org/10.3389/fimmu.2022.894110

Ejemplares similares